Business Context and Reporting Period
This Form 8-K filing by Akebia Therapeutics, Inc. (AKBA) covers the event date of May 22, 2023. The report addresses the company's listing status on The Nasdaq Capital Market following a period of non-compliance with minimum bid price requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance metrics.
Material Changes
The primary material change is the resolution of a delisting threat. On May 22, 2023, Nasdaq confirmed that Akebia Therapeutics regained compliance with the $1.00 per share minimum bid price requirement (Listing Rule 5550(a)(2)). This reverses a prior notification on May 9, 2023, which stated the company had failed to regain compliance and was subject to delisting.
Outlook, Risks, and Management Commentary
- Delisting Risk Resolved: The scheduled appeal hearing before the Nasdaq Hearings Panel, originally set for June 22, 2023, has been cancelled.
- Listing Status: The company's securities will continue to be listed and traded on The Nasdaq Capital Market.
- Management Action: The company issued a press release on May 22, 2023, announcing the compliance notice.
Investor Verification Checklist
- Verify the current trading price of AKBA to ensure it remains above the $1.00 minimum bid price threshold.
- Review the attached press release (Exhibit 99.1) for any additional commentary on the company's capitalization or market conditions.
- Monitor future filings for any recurrence of bid price non-compliance.